CANbridge Says C5 mAb Effective in Early Trial for Complement Diseases
publication date: Feb 7, 2022
CANbridge Pharma of Beijing reported positive data from a Singapore Phase I trial of its long-acting anti-C5 complement recombinant human mAb. CAN106 is a novel, long-acting mAb designed to neutralize C5, a key component of the complement system. In patients with paroxysmal nocturnal hemoglobinuria (PNH), division of C5 can cause cell lysis of red blood cells. The Phase I trial showed CAN106 to be well-tolerated while lowering levels of free C5 by 99%. CANbridge, a rare disease and oncology company, has also been approved to start CAN106 trials in China for PNH. More details....
Stock Symbol: (HK: 1228)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.